Empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: a systematic review and network meta-analysis of randomized controlled trials

Abstract

BackgroundThe optimal empiric antibiotic regimen for non–ventilator-associated hospital-acquired pneumonia (HAP) is uncertain. ObjectivesTo compare the effectiveness and safety of alternative empiric antibiotic regimens in HAP using a network meta-analysis. Data sourcesMedline, EMBASE, Cochrane CENTRAL, Web of Science, and CINAHL from database inception to July 06, 2023. Study eligibility criteriaRCTs. ParticipantsAdults with clinical suspicion of HAP. InterventionsAny empiric antibiotic regimen vs. another, placebo, or no treatment. Assessment of risk of biasPaired reviewers independently assessed risk of bias using a modified Cochrane tool for assessing risk of bias in randomized trials. Methods of data synthesisPaired reviewers independently extracted data on trial and patient characteristics, antibiotic regimens, and outcomes of interest. We conducted frequentist random-effects network meta-analyses for treatment failure and all-cause mortality and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. ResultsThirty-nine RCTs proved eligible. Thirty RCTs involving 4807 participants found low certainty evidence that piperacillin-tazobactam (RR compared to all cephalosporins: 0.65; 95% CI: 0.42, 1.01) and carbapenems (RR compared to all cephalosporins: 0.77; 95% CI: 0.53, 1.11) might be among the most effective in reducing treatment failure. The findings were robust to the secondary analysis comparing piperacillin-tazobactam vs. antipseudomonal cephalosporins or antipseudomonal carbapenems vs. antipseudomonal cephalosporins. Eleven RCTs involving 2531 participants found low certainty evidence that ceftazidime and linezolid combination may not be convincingly different from cephalosporin alone in reducing all-cause mortality. Evidence on other antibiotic regimens is very uncertain. Data on other patient-important outcomes including adverse events was sparse, and we did not perform network or pairwise meta-analysis. ConclusionsFor empiric antibiotic therapy of adults with HAP, piperacillin-tazobactam might be among the most effective in reducing treatment failure. Empiric methicillin-resistant Staphylococcus aureus coverage may not exert additional benefit in reducing mortality. RegistrationPROSPERO (CRD 42022297224).